acqua+
ONDA NITRICA
gli diamo un 10% max e che nn rompano le palle.......
tanto per loro sta molecola era una cioffeca
10% !!!!!!!!
,,, facciamo un 2/3% max
NicOx : Garufi ... e la Rivoluzione Pharma (8 lettori)
- Creatore Discussione Yesod
- Data di Inizio
- Stato
10% !!!!!!!!
,,, facciamo un 2/3% max
acqua+
ONDA NITRICA
abbandonare definitivamente???
te lo chiedo perchè visto che hanno qualcosa in ballo nella retinopatia diabetica e , se nn è questa, c'è pure questa molecola Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.
come fanno a lasciare la tecnologia nitrica alla vigilia della scadenza del brevetto XALATAN nel 2011
merçi
era un Comunicato di 1 mesetto addietro ,,,, il buon Mago sarà + esauriente
DickSIM
Prima o poi....ci becco!
DickSIM
Prima o poi....ci becco!
era un Comunicato di 1 mesetto addietro ,,,, il buon Mago sarà + esauriente
questa è nuova per me acquttina........... vorrei vedere il comunicato... 3 marzo 2009..............
NEW YORK & ROCHESTER, N.Y.--(BUSINESS WIRE)--Pfizer Inc and Bausch & Lomb announced today a co-promotion agreement involving both companies’ prescription ophthalmic pharmaceuticals in the United States. The agreement will allow both companies to greatly increase the level of eye care industry support for these important medications that treat serious ophthalmic conditions.
The five-year agreement includes Pfizer’s Xalatan® (latanoprost ophthalmic solution) and Bausch & Lomb’s Alrex® (loteprednol etabonate ophthalmic suspension 0.2%), Lotemax® (loteprednol etabonate ophthalmic suspension 0.5%) and Zylet® (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension). The co-promotion agreement also will apply to Bausch & Lomb’s investigational anti-infective eye drop, besifloxacin ophthalmic suspension, 0.6%, which is currently under review by the U.S. Food and Drug Administration (FDA).
Under the terms of the agreement, both the Pfizer and Bausch & Lomb sales forces will promote Xalatan, Alrex, Lotemax, Zylet and besifloxacin (subject to FDA approval).
“Ophthalmic disorders cause significant disability in the United States. This agreement with Bausch & Lomb combines our portfolios and further demonstrates our commitment to provide prescription medications that can benefit people living with serious eye conditions,” said Olivier Brandicourt, president and general manager, Pfizer's Specialty Care business unit.
Separate from this co-promotion agreement with Bausch & Lomb, Pfizer will continue to maintain three mid-stage ophthalmic development programs in its own pipeline.
“Working in collaboration, our U.S. sales organizations will now represent one of the broadest product offerings in the U.S. ophthalmic market,” said Flemming Ornskov, M.D., MPH, corporate vice president and global president, Pharmaceuticals, Bausch & Lomb. “We’ll be able to reach considerably more eye care practitioners, and in turn, better attend to the needs of millions of patients every year.”
In December 2008, the FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee voted unanimously to recommend approval of besifloxacin for the treatment of bacterial conjunctivitis. Bausch & Lomb anticipates a decision from the FDA in 2009.
Financial terms of the agreement were not disclosed.
About Pfizer Ophthalmics
Pfizer Ophthalmics, part of Pfizer’s Specialty Care business unit, is committed to preserving sight and eliminating preventable blindness and expanding its portfolio through licensing and partnerships. Pfizer Ophthalmics discovers, develops and provides leading treatments in ophthalmology to support patients who are at risk of blindness or suffering from vision impairment, and to serve the health care professionals who treat them. The Xalabrand franchise is a leading contributor to Pfizer’s sales worldwid
DickSIM
Prima o poi....ci becco!
un anno fa........... il buon Michele..........su Pfizer..............
Michele Garufi, Chairman and Chief Executive Officer of NicOx, commented. “We believe these results for PF-
03187207 suggest nitric oxide donation can bring therapeutic benefit through improved intraocular pressure lowering.
Although Pfizer has decided that PF-03187207 does not meet its specific requirements for the US and European
markets, we believe this phase 2 study demonstrates a clear commercial potential for PF-03187207 and we are
exploring possible strategies with Pfizer to unlock this value. Moreover, the promising results from our joint research
program make us confident that a follow-up candidate will be selected by Pfizer with the potential for further improvement
over existing treatments.”
Michele Garufi, Chairman and Chief Executive Officer of NicOx, commented. “We believe these results for PF-
03187207 suggest nitric oxide donation can bring therapeutic benefit through improved intraocular pressure lowering.
Although Pfizer has decided that PF-03187207 does not meet its specific requirements for the US and European
markets, we believe this phase 2 study demonstrates a clear commercial potential for PF-03187207 and we are
exploring possible strategies with Pfizer to unlock this value. Moreover, the promising results from our joint research
program make us confident that a follow-up candidate will be selected by Pfizer with the potential for further improvement
over existing treatments.”
DickSIM
Prima o poi....ci becco!
caro doc siamo da 1 anno in fase di lateralizzazione......... 
che si è accentuata in questo ultimo mese....... 
serve uno shake! se no qui si continua per un altro mesetto !!! 
per Vicsim>>>>> situazione di A.T
auspico chiusura sopra i 9.80€ con volumi.............per vedere poi accelerazione over 10€!
che si è accentuata in questo ultimo mese....... serve uno shake!
se no qui si continua per un altro mesetto !!! per Vicsim
>>>>> situazione di A.Tauspico chiusura sopra i 9.80€ con volumi.............per vedere poi accelerazione over 10€!
Prezzemolo
numero magico 000074130
farmacia10
el pueblo unido...
jenJEN
Mai domi!
mi associoi vecchi soffrono in silenzio ma non mollano
bentornato
- Stato